Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.
Fiche publication
Date publication
mars 2018
Journal
The lancet. HIV
Auteurs
Membres identifiés du Cancéropôle Est :
Dr WIRTH Nathalie
Tous les auteurs :
Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G,
Lien Pubmed
Résumé
Tobacco smoking is common in people living with HIV, but high-quality evidence on interventions for smoking cessation is not available in this population. We aimed to assess the efficacy and safety of varenicline with counselling to aid smoking cessation in people living with HIV.
Mots clés
Adult, Counseling, Double-Blind Method, Drug Administration Schedule, Female, France, HIV Infections, complications, Humans, Male, Middle Aged, Nicotinic Agonists, administration & dosage, Smoking, drug therapy, Treatment Outcome, Varenicline, administration & dosage
Référence
Lancet HIV. 2018 03;5(3):e126-e135